Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded use area of Klisyri to up to 100 cm 2 on the face and scalp for the treatment ...

Newly published data confirm that daily topical tirbanibulin (Klisyri) was effective at treating actinic keratosis lesions on the face and scalp in two phase III trials. In two identical double-blind ...

The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp. The Food ...

The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials (ClinicalTrials.gov: NCT03285477 [N=351] and NCT03285490 [N=351]) that compared the efficacy and safety of ...

- Actinic keratosis (AK), the second most common diagnosis made by dermatologists in the United States(1), affects more than 40 million Americans each year(2) - Klisyri® (tirbanibulin) met the primary ...

Tirbanibulin ointment 1% shows good safety and tolerability in the treatment of actinic keratosis (AK) in fields of up to 100 cm 2 on the face and scalp. The most common local effects of treatment ...

BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

Pharmacology: The mechanism of action by which ingenol mebutate induces cell death in treating actinic keratosis lesions is unknown. Clinical trials: In two double-blind, vehicle-controlled, clinical ...

Graceway® Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara TM, determining it to be safe and effective for the ...

WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall ...